Dihexa
Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB0408
The most potent cognitive enhancer yet studied — 10 million times more potent than BDNF at synaptic formation.
Molecular structure image coming soon
Research use only. Very limited human safety data. Extremely potent — use with caution and under qualified supervision.
Overview
Dihexa is a small peptide derived from Angiotensin IV that has demonstrated extraordinary potency in cognitive enhancement models. Research at Washington State University showed it was 10 million times more potent than BDNF in facilitating synaptogenesis (new synapse formation). It is being investigated for Alzheimer's disease, cognitive impairment, and social cognition deficits.
Mechanism of Action
Dihexa binds to hepatocyte growth factor (HGF) and potentiates its receptor c-Met, leading to profound synaptic growth and cognitive enhancement. This pathway is distinct from all other known cognitive enhancers, making Dihexa potentially useful in treatment-resistant cognitive conditions.
Use Cases
- ✓Alzheimer's disease and dementia (research)
- ✓Cognitive enhancement in healthy individuals
- ✓Recovery from traumatic brain injury
- ✓Social cognition improvement
- ✓Age-related cognitive decline
Research Summary
Animal studies from WSU demonstrate remarkable reversal of cognitive deficits in aged rats and disease models. The synaptogenic potency exceeds BDNF by orders of magnitude. Human research is in early stages. Currently one of the most discussed cognitive peptides in longevity and biohacking communities.
Typical Dosing
Research doses: 0.1–10 mg/kg in animal studies. Human protocols in practice range from 10–30 mg oral or 1–5 mg subcutaneous.
Administration
Research Chemical
Research use only. Very limited human safety data. Extremely potent — use with caution and under qualified supervision.
